Alirocumab and Plaque Burden In Familial Hypercholesterolaemia
Status:
Completed
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
Low-level, open-label, multicenter clinical trial to evaluate the effect of alirocumab on the
volume, architecture and composition of atherosclerotic plaque in patients with Familial
hypercholesterolemia from the SAFEHEART Registry. ARCHITECT study